Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 10/20 | 0.75 |
| ▸ | PFKFB4 | Q16877 | 9/20 | 0.75 |
| ▸ | CMA1 | P23946 | 5/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5621758 | 0.90 | PFKFB3 (0.80) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL8255568 | 0.88 | CMA1 (0.80) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL12204617 | 0.86 | NPSR1 (0.90) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL788108 | 0.86 | PFKFB4 (1.00) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL15480585 | 0.86 | CMA1 (0.77) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL27685 | 0.85 | PFKFB4 (0.66) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL2908164 | 0.85 | CMA1 (0.76) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL5622890 | 0.83 | CMA1 (0.55) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| Propane SCHEMBL28642185 | 0.83 | PFKFB4 (0.94) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 | |
| SCHEMBL2910759 | 0.83 | CMA1 (0.82) | PFKFB3PFKFB4CMA1NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-7399781-B2 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-7071220-B2 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20060116408-A1 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| US-20030229126-A1 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116408-A1 | N-substituted benzothiophenesulfonamide derivatives | ECE1, ECE2, CMA1 | PFKFB3 4040/4885PFKFB4 4092/4885CMA1 3/4885 |
| US-20030229126-A1 | N-substituted benzothiophenesulfonamide derivatives | ECE1, ECE2, CMA1 | PFKFB3 4040/4885PFKFB4 4092/4885CMA1 3/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | PFKFB3 3217/4885PFKFB4 2964/4885CMA1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.